Loop F of the GABAA receptor alpha subunit governs GABA potency. 2018

Adrienn Pálvölgyi, and Krisztina Móricz, and Ágnes Pataki, and Balázs Mihalik, and Gábor Gigler, and Katalin Megyeri, and Szabolcs Udvari, and István Gacsályi, and Ferenc A Antoni
Division of Preclinical Research, Egis Pharmaceuticals PLC, Budapest, Hungary.

Gamma-amino butyric acid (GABA) is an abundant neurotransmitter in the CNS. GABAergic interneurons orchestrate pyramidal neurons in the cerebral cortex, and thus control learning and memory. Ionotropic receptors for GABA (GABAAR) are heteropentameric complexes of α, β and γ integral membrane-protein subunits forming Cl- -channels operated by GABA, which are vital for brain function and are important drug targets. However, knowledge on how GABAAR bind GABA is controversial. Structural biology versus functional modelling combined with site-directed mutagenesis suggest markedly different roles for loop F of the extracellular domain of the α-subunit when complexed with GABA. Here, we report that contrary to the results of structural studies, loop F of the α-subunit controls the potency of GABA on GABAAR. We examined the effect of replacing a short, variable segment of loop F of the GABAA α5-subunit with the corresponding segment of the α2-subunit (GABAA5_LF2) and vice versa (GABAA2-LF5). When compared with their respective wild-type counterparts, GABAA5_LF2 receptors displayed enhanced sensitivity towards GABA, whilst in GABAA2-LF5 sensitivity was diminished. Mice homozygous for the genetic knock-in of the GABAA5_LF2 subunit showed a marked deficit in long- but not short-term object recognition memory. Working memory in place learning, spontaneous alternation and the rewarded T-maze were all normal. The deficit in long-term recognition memory was reversed by an α5-GABAA negative allosteric modulator compound. The data show that loop F governs GABA potency in a receptor isoform-specific manner in vitro. Moreover, this mechanism of ligand recognition appears to be operative in vivo and impacts cognitive performance.

UI MeSH Term Description Entries
D008297 Male Males
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011963 Receptors, GABA-A Cell surface proteins which bind GAMMA-AMINOBUTYRIC ACID and contain an integral membrane chloride channel. Each receptor is assembled as a pentamer from a pool of at least 19 different possible subunits. The receptors belong to a superfamily that share a common CYSTEINE loop. Benzodiazepine-Gaba Receptors,GABA-A Receptors,Receptors, Benzodiazepine,Receptors, Benzodiazepine-GABA,Receptors, Diazepam,Receptors, GABA-Benzodiazepine,Receptors, Muscimol,Benzodiazepine Receptor,Benzodiazepine Receptors,Benzodiazepine-GABA Receptor,Diazepam Receptor,Diazepam Receptors,GABA(A) Receptor,GABA-A Receptor,GABA-A Receptor alpha Subunit,GABA-A Receptor beta Subunit,GABA-A Receptor delta Subunit,GABA-A Receptor epsilon Subunit,GABA-A Receptor gamma Subunit,GABA-A Receptor rho Subunit,GABA-Benzodiazepine Receptor,GABA-Benzodiazepine Receptors,Muscimol Receptor,Muscimol Receptors,delta Subunit, GABA-A Receptor,epsilon Subunit, GABA-A Receptor,gamma-Aminobutyric Acid Subtype A Receptors,Benzodiazepine GABA Receptor,Benzodiazepine Gaba Receptors,GABA A Receptor,GABA A Receptor alpha Subunit,GABA A Receptor beta Subunit,GABA A Receptor delta Subunit,GABA A Receptor epsilon Subunit,GABA A Receptor gamma Subunit,GABA A Receptor rho Subunit,GABA A Receptors,GABA Benzodiazepine Receptor,GABA Benzodiazepine Receptors,Receptor, Benzodiazepine,Receptor, Benzodiazepine-GABA,Receptor, Diazepam,Receptor, GABA-A,Receptor, GABA-Benzodiazepine,Receptor, Muscimol,Receptors, Benzodiazepine GABA,Receptors, GABA A,Receptors, GABA Benzodiazepine,delta Subunit, GABA A Receptor,epsilon Subunit, GABA A Receptor,gamma Aminobutyric Acid Subtype A Receptors
D005106 Exploratory Behavior The tendency to explore or investigate a novel environment. It is considered a motivation not clearly distinguishable from curiosity. Curiosity,Novelty-Seeking Behavior,Behavior, Exploratory,Behavior, Novelty-Seeking,Behaviors, Exploratory,Behaviors, Novelty-Seeking,Curiosities,Exploratory Behaviors,Novelty Seeking Behavior,Novelty-Seeking Behaviors
D005680 gamma-Aminobutyric Acid The most common inhibitory neurotransmitter in the central nervous system. 4-Aminobutyric Acid,GABA,4-Aminobutanoic Acid,Aminalon,Aminalone,Gammalon,Lithium GABA,gamma-Aminobutyric Acid, Calcium Salt (2:1),gamma-Aminobutyric Acid, Hydrochloride,gamma-Aminobutyric Acid, Monolithium Salt,gamma-Aminobutyric Acid, Monosodium Salt,gamma-Aminobutyric Acid, Zinc Salt (2:1),4 Aminobutanoic Acid,4 Aminobutyric Acid,Acid, Hydrochloride gamma-Aminobutyric,GABA, Lithium,Hydrochloride gamma-Aminobutyric Acid,gamma Aminobutyric Acid,gamma Aminobutyric Acid, Hydrochloride,gamma Aminobutyric Acid, Monolithium Salt,gamma Aminobutyric Acid, Monosodium Salt
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Adrienn Pálvölgyi, and Krisztina Móricz, and Ágnes Pataki, and Balázs Mihalik, and Gábor Gigler, and Katalin Megyeri, and Szabolcs Udvari, and István Gacsályi, and Ferenc A Antoni
February 2008, The Journal of biological chemistry,
Adrienn Pálvölgyi, and Krisztina Móricz, and Ágnes Pataki, and Balázs Mihalik, and Gábor Gigler, and Katalin Megyeri, and Szabolcs Udvari, and István Gacsályi, and Ferenc A Antoni
September 1993, European journal of pharmacology,
Adrienn Pálvölgyi, and Krisztina Móricz, and Ágnes Pataki, and Balázs Mihalik, and Gábor Gigler, and Katalin Megyeri, and Szabolcs Udvari, and István Gacsályi, and Ferenc A Antoni
April 2003, The Journal of biological chemistry,
Adrienn Pálvölgyi, and Krisztina Móricz, and Ágnes Pataki, and Balázs Mihalik, and Gábor Gigler, and Katalin Megyeri, and Szabolcs Udvari, and István Gacsályi, and Ferenc A Antoni
March 2017, The Journal of physiology,
Adrienn Pálvölgyi, and Krisztina Móricz, and Ágnes Pataki, and Balázs Mihalik, and Gábor Gigler, and Katalin Megyeri, and Szabolcs Udvari, and István Gacsályi, and Ferenc A Antoni
July 2001, Toxicology letters,
Adrienn Pálvölgyi, and Krisztina Móricz, and Ágnes Pataki, and Balázs Mihalik, and Gábor Gigler, and Katalin Megyeri, and Szabolcs Udvari, and István Gacsályi, and Ferenc A Antoni
January 1992, Advances in biochemical psychopharmacology,
Adrienn Pálvölgyi, and Krisztina Móricz, and Ágnes Pataki, and Balázs Mihalik, and Gábor Gigler, and Katalin Megyeri, and Szabolcs Udvari, and István Gacsályi, and Ferenc A Antoni
February 2005, Science's STKE : signal transduction knowledge environment,
Adrienn Pálvölgyi, and Krisztina Móricz, and Ágnes Pataki, and Balázs Mihalik, and Gábor Gigler, and Katalin Megyeri, and Szabolcs Udvari, and István Gacsályi, and Ferenc A Antoni
January 1997, Alcohol health and research world,
Adrienn Pálvölgyi, and Krisztina Móricz, and Ágnes Pataki, and Balázs Mihalik, and Gábor Gigler, and Katalin Megyeri, and Szabolcs Udvari, and István Gacsályi, and Ferenc A Antoni
August 2008, Journal of medicinal chemistry,
Adrienn Pálvölgyi, and Krisztina Móricz, and Ágnes Pataki, and Balázs Mihalik, and Gábor Gigler, and Katalin Megyeri, and Szabolcs Udvari, and István Gacsályi, and Ferenc A Antoni
January 1996, Hippocampus,
Copied contents to your clipboard!